The role of aromatase inactivators in the treatment of breast cancer

International Journal of Clinical Oncology

Volumn 7, Issue 4, 2002, Pages 265-270

  Lønning, Per Eystein ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Aromatase; Breast cancer; Endocrine therapy; Estrogens

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; PLACEBO; PYRIDOGLUTETHIMIDE; TAMOXIFEN; VOROZOLE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CROSS RESISTANCE; DRUG DISPOSITION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG REEXPOSURE; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HUMAN; METASTASIS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS;

EID: 18544373175     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200038     Document Type: Conference Paper

References (81)

1. Steroid receptors in human breast cancer
2. Tamoxifen for patients with estrogen receptor-negative breast cancer
3. Estrogen receptor alpha in human breast cancer: Occurrence and significance
4. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
5. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
6. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
7. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial
8. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
9. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study
10. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
11. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
12. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
13. Breast cancer: Chemotherapy in the treatment of advanced disease
14. Endocrine treatment of breast cancer in women
15. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer
16. Third line chemotherapy in patients with metastatic breast cancer: An evaluation of quality of life and cost
17. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer
18. Antiaromatase agents: Preclinical data and neoadjuvant therapy
19. Endocrine activity of the postmenopausal ovary: The effects of pituitary down-regulation and oophorectomy
20. Resistance of the ovary to blockade of aromatization with aminoglutethimide
21. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer
22. Aromatization inhibition alone or in combination with GmRH agonists for the treatment of premenopausal breast cancer patients
23. Aberrant expression of aromatase in breast cancer tissues
24. Endocrine disorders associated with inappropriately high aromatase expression
25. Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction
26. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome p450 gene expression in human adipose tissue
27. A unique aromatase (P-450 arom) mRNA formed by alternative use of tissue-specific exons 1 in human skin fibroblasts
28. Breast cancer and the role of cytokines in regulating estrogen synthesis: An emerging hypothesis
29. Estrogen biosynthesis in adipose tissue: Regulation by paracrine and autocrine mechanisms
30. Do intracrine mechanisms regulate aromatase expression?
31. In situ oestrone synthesis in normal breast and breast tumour tissue: Effect of treatment with 4-hydroxyandrostenedione
32. Importance of intratumour aromatase, and its susceptibility to inhibitors
33. Aromatase inhibitors in the treatment of advanced breast cancer
34. Stepwise estrogen suppression manipulating the estrostat
35. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
36. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer
37. Measurement of aromatisation by a urine technique suitable for the evaluation ofaromatase inhibitors in vivo
38. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
39. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients
40. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
41. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer
42. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: Effects on aromatase inhibition and oestrogen suppression
43. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in postmenopausal breast cancer patients
44. Influence of anastrozole (Arimidex®), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
45. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
46. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study
47. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women
48. Pharmacokinetics (PK) of Aromasin(R) (exemestane, EXE) after single and repeated doses in healthy postmenopausal volunteers (HPV)
49. Exemestane: A review of its clinical efficacy and safety
50. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study
51. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
52. Aromatase inhibition with 4-OHandrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
53. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (Anastrozole and letrozole): Is a clinical benefit still achievable?
54. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
55. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen and megace
56. Progestins in breast cancer treatment
57. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients
58. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
59. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
60. Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in first line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn
61. The potential for aromatase inhibition in breast cancer prevention
62. Prevention and management of osteoporosis. Current trends and future prospects
63. Selective oestrogen receptor modulators: Potential therapeutic applications
64. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women
65. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
66. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial
67. Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen
68. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer
69. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
70. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
71. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
72. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
73. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women. A 2-year, placebo-controlled study
74. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial
75. Relation between apolipoprotein E phenotype and the changes in lipids during tamoxifen treatment
76. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women
77. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen
78. Effect of non-steroidal aromatase inhibitors (AI) on serum lipid profiles in patients with breast cancer. Preliminary report
79. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer
80. No adverse impact on serum lipids of the irreversible aromatase inactivator aromasin (R) (Exemestane (E)) in first line treatment of metastatic breast cancer (MBC): Companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia and Upjohn
81. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer